Lymphoma

8 protocols meet the specified criteria.
  • A051901

    Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
  • CCTL019B2003I

    Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
  • EA4151

    A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)
  • JCAR017-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release
  • KT-US-472-0141

    Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication
  • NCBP6637-01

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients